The Record
A living scoreboard for the question this whole site is watching: whether legitimate melanocortin photoprotection reaches people faster than the gray market can sell the counterfeit. The dated catalysts ahead, the ones already settled, and where Melanotan II legally stands right now.
Dated decisions and readouts still ahead, soonest first.
The confirmatory study of around 300 patients, planned for the second half of 2026, meant to underpin regulatory filings across Europe, North America and Africa. Its design received final EMA scientific advice in April 2026.
Topline from the 200-patient CUV105 trial of SCENESSE in vitiligo — the approved MC1R agonist reaching for its second indication. A positive result widens the beachhead.
The FDA’s Pharmacy Compounding Advisory Committee is due to consider whether MT-II can move off the restricted Category 2 list and become compoundable. The first time its U.S. legitimacy is formally on a calendar — and the single most consequential date here.
The New Drug Application for dersimelagon (MT-7117) in EPP and X-linked protoporphyria has been accepted under priority review, with a decision expected around the end of February 2027. If approved, melanocortin photoprotection reaches patients as a once-daily pill for the first time — still for a rare disease, not a tan. Context in The pipeline right now.
The milestones that shaped the picture above, most recent first.
Five seized ‘Pure Tans Triple Strength’ bottles from the same NSW seller already fined $101,412 in May. The label was not a specification.
Afamelanotide adds another country — the first systemic photoprotectant keeps spreading through the front door.
Final scientific advice from the European regulator on the CUV107 pivotal study — the step that turns a vitiligo programme into a filing path. Afamelanotide’s second indication now has a regulator’s fingerprints on its design.
HHS moved roughly 14 of 19 restricted peptides back toward the compoundable Category 1; Melanotan II was among the ~5 held back. The door stayed shut.
Placed alongside heroin and LSD; possession without a research licence becomes a criminal offence. Triggered by 89 adverse-event reports (2022–25), including two melanoma cases within 18 months of use.
Dersimelagon — a once-daily pill, not an implant — met its primary endpoint in the 165-patient INSPIRE study in EPP and X-linked protoporphyria. Melanocortin photoprotection escaping the needle is the clearest sign yet the class is advancing; the FDA has since accepted the filing under priority review (see the calendar above).
A written answer: injectables are unlicensed medicines; nasal sprays without medical claims are not regarded as medicinal products, so they are not in the MHRA’s remit. The gap, on the record.
Europe widens the approved use of the first systemic photoprotectant.
Designated a bulk substance that “may present significant safety risks” — which is what closed the compounding door in the first place.
The first melanocortin agonist approved in the U.S. for a photoprotective use. Proof the approval door opens.
Afamelanotide authorised for EPP under exceptional circumstances; the class’s first market approval anywhere.
The unapproved compound, jurisdiction by jurisdiction.
United States
Unapproved · not compoundableNo approved indication; Category 2, so licensed pharmacies can’t compound it; illegal to market for human use. The FDA has sent warning letters to distributors. Compounding status under review in 2027.
United Kingdom
Illegal to sell · legal to possessAn unlicensed medicine the MHRA bars from sale — it warned the public in 2008 and later helped suspend over 100 trading websites. Sold instead as a “cosmetic” nasal spray through a gap between the rulebooks that the DHSC confirmed to Parliament in Dec 2025. Selling is illegal; using is not.
Australia
Schedule 9 · prohibitedSince Feb 2026, the strictest classification there is — the same schedule as heroin and LSD. Possession without a research licence is a criminal offence. The toughest market in the world for MT-II.
EU & Nordics
Unapproved · banned as cosmeticNo approved indication anywhere in the EU; banned as a cosmetic in Denmark and others. Ireland’s HPRA warns it is not authorised to treat anything and ordered more than 500 online ads removed between 2020 and 2022. Country by country: The enforcement map.
The counterweight to all that restriction: the legitimate melanocortin agonists that reached patients the right way — and the pipeline behind them.
Afamelanotide (SCENESSE)
MC1R agonist · subcutaneous implant
Approved for EPP in the EU (2014), U.S. (2019), Australia (2020), Israel, and Canada (2026). Now in Phase III for vitiligo, with a readout due Dec 2026.
Dersimelagon (MT-7117)
MC1R agonist · once-daily oral pill
Positive Phase 3 (INSPIRE) in EPP and X-linked protoporphyria (Jan 2026); New Drug Application accepted by the FDA under priority review, decision expected around the end of Feb 2027. The first oral entrant in the class — no needle, no implant.
The through-line: as the legitimate technology keeps advancing — approvals, new indications, an oral entrant — Melanotan II keeps getting walled off further. Those two trends are the whole story. For how a legitimate melanocortin sun drug actually reaches Americans, readThe three doors; for the gray market it competes with, The Barbie drug; for what the warnings actually did, a decade of enforcementand the enforcement map; for where the legitimate programs stand, the pipeline right now; for the full arc, the timeline.